These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 26726953)

  • 1. Inhibition of Octreotide Acylation Inside PLGA Microspheres by Derivatization of the Amines of the Peptide with a Self-Immolative Protecting Group.
    Shirangi M; Najafi M; Rijkers DT; Kok RJ; Hennink WE; van Nostrum CF
    Bioconjug Chem; 2016 Mar; 27(3):576-85. PubMed ID: 26726953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions.
    Murty SB; Goodman J; Thanoo BC; DeLuca PP
    AAPS PharmSciTech; 2003 Oct; 4(4):E50. PubMed ID: 15198545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Assessment of Octreotide Acylation in Polyester Microspheres by LC-MS/MS.
    Shirangi M; Hennink WE; Somsen GW; van Nostrum CF
    Pharm Res; 2015 Sep; 32(9):3044-54. PubMed ID: 25832500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide).
    Na DH; DeLuca PP
    Pharm Res; 2005 May; 22(5):736-42. PubMed ID: 15906168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres.
    Ghassemi AH; van Steenbergen MJ; Barendregt A; Talsma H; Kok RJ; van Nostrum CF; Crommelin DJ; Hennink WE
    Pharm Res; 2012 Jan; 29(1):110-20. PubMed ID: 21744173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles.
    Vaishya RD; Mandal A; Gokulgandhi M; Patel S; Mitra AK
    Int J Pharm; 2015 Jul; 489(1-2):237-45. PubMed ID: 25940041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible blocking of amino groups of octreotide for the inhibition of formation of acylated peptide impurities in poly(lactide-co-glycolide) delivery systems.
    Ahn JH; Park EJ; Lee HS; Lee KC; Na DH
    AAPS PharmSciTech; 2011 Dec; 12(4):1220-6. PubMed ID: 21935743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended release microparticle-in-gel formulation of octreotide: Effect of polymer type on acylation of peptide during in vitro release.
    Vaishya RD; Mandal A; Patel S; Mitra AK
    Int J Pharm; 2015 Dec; 496(2):676-88. PubMed ID: 26561725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of peptide acylation in PLGA microspheres with water-soluble divalent cationic salts.
    Zhang Y; Sophocleous AM; Schwendeman SP
    Pharm Res; 2009 Aug; 26(8):1986-94. PubMed ID: 19533307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aqueous remote loading of model cationic peptides in uncapped poly(lactide-co-glycolide) microspheres for long-term controlled release.
    Liang D; Frank S; Schwendeman SP
    Drug Deliv Transl Res; 2024 Mar; 14(3):696-704. PubMed ID: 38038895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acylation of arginine in goserelin-loaded PLGA microspheres.
    Shirangi M; Hennink WE; Somsen GW; van Nostrum CF
    Eur J Pharm Biopharm; 2016 Feb; 99():18-23. PubMed ID: 26607434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation.
    Murty SB; Na DH; Thanoo BC; DeLuca PP
    Int J Pharm; 2005 Jun; 297(1-2):62-72. PubMed ID: 15885939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimizing acylation of peptides in PLGA microspheres.
    Zhang Y; Schwendeman SP
    J Control Release; 2012 Aug; 162(1):119-26. PubMed ID: 22546683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide acylation by poly(alpha-hydroxy esters).
    Lucke A; Kiermaier J; Göpferich A
    Pharm Res; 2002 Feb; 19(2):175-81. PubMed ID: 11883645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of inhibitors of peptide sorption and acylation in PLGA.
    Sophocleous AM; Zhang Y; Schwendeman SP
    J Control Release; 2009 Aug; 137(3):179-84. PubMed ID: 19318114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method.
    Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Schwendeman SP
    Drug Deliv Transl Res; 2022 Mar; 12(3):695-707. PubMed ID: 34215997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
    Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
    J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimizing the initial burst of octreotide acetate from glucose star PLGA microspheres prepared by the solvent evaporation method.
    Beig A; Ackermann R; Wang Y; Schutzman R; Schwendeman SP
    Int J Pharm; 2022 Aug; 624():121842. PubMed ID: 35609832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly(D,L-lactide-co-glycolide) microspheres.
    Wang J; Wang BM; Schwendeman SP
    Biomaterials; 2004 May; 25(10):1919-27. PubMed ID: 14738856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical-Chemical Characterization of Octreotide Encapsulated in Commercial Glucose-Star PLGA Microspheres.
    Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Qin B; Schwendeman SP
    Mol Pharm; 2020 Nov; 17(11):4141-4151. PubMed ID: 32876463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.